[
  {
    "ts": null,
    "headline": "Amgen’s Weight-Loss Drug Shows Promise With Less Frequent Dosing",
    "summary": "Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator from Eli Lilly and Novo Nordisk.",
    "url": "https://finnhub.io/api/news?id=2e96d36c64fc6d1861ba3195c8158701ef3c48a440537ddb742cbdee3f0525dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768513200,
      "headline": "Amgen’s Weight-Loss Drug Shows Promise With Less Frequent Dosing",
      "id": 138137483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator from Eli Lilly and Novo Nordisk.",
      "url": "https://finnhub.io/api/news?id=2e96d36c64fc6d1861ba3195c8158701ef3c48a440537ddb742cbdee3f0525dd"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. (AMGN): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Amgen Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc.’s share was trading at $325.54 as of January 12th. AMGN’s trailing and forward P/E were 25.18 and 14.79 respectively according to Yahoo Finance. Amgen Inc. discovers, develops, manufactures, and […]",
    "url": "https://finnhub.io/api/news?id=3c61b6e1edca0646e36140886e9bc4f17e418b5529e6d0ae0c096200836b10b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768503121,
      "headline": "Amgen Inc. (AMGN): A Bull Case Theory",
      "id": 138126500,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Amgen Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc.’s share was trading at $325.54 as of January 12th. AMGN’s trailing and forward P/E were 25.18 and 14.79 respectively according to Yahoo Finance. Amgen Inc. discovers, develops, manufactures, and […]",
      "url": "https://finnhub.io/api/news?id=3c61b6e1edca0646e36140886e9bc4f17e418b5529e6d0ae0c096200836b10b5"
    }
  }
]